Urological oncology is a subject of enormous interest to large numbers of uro- gists throughout the world, particularly with our increasing understanding of the possible causes and pathogenesis of the condition. As Editor-in-Chief of one of the urological journals, I can attest to this interest; the largest percentage of the papers I receive for review each year relate to either clinical or experime- tal urological oncology. It used to be that the manuscripts concerned mainly surgical techniques, but now this has extended to new technologies, dia- nostic methods, randomized pharmaceutical clinical trials, and thoughtful and complex experimental studies into the genesis of urological cancer. This is all evidence of our increasing interest in the topic. In addition to this, we have come to understand the management of urolo- cal cancer is not in the hands of a single discipline. The advent of multidis- plinary team meetings has made us realize that there is a hugely signi? cant role to be played by urologists, medical oncologists, radiation oncologists, patho- gists, and radiologists. This new dimension has been driven by the advent of new therapies and by closer interaction among all of these groups at academic meetings. This is to be applauded and has inevitably lead to improvements in the management of our patients.

Urological oncology is a subject of enormous interest to large numbers of uro- gists throughout the world, particularly with our increasing understanding of the possible causes and pathogenesis of the condition. As Editor-in-Chief of one of the urological journals, I can attest to this interest; the largest percentage of the papers I receive for review each year relate to either clinical or experime- tal urological oncology. It used to be that the manuscripts concerned mainly surgical techniques, but now this has extended to new technologies, dia- nostic methods, randomized pharmaceutical clinical trials, and thoughtful and complex experimental studies into the genesis of urological cancer. This is all evidence of our increasing interest in the topic. In addition to this, we have come to understand the management of urolo- cal cancer is not in the hands of a single discipline. The advent of multidis- plinary team meetings has made us realize that there is a hugely signi? cant role to be played by urologists, medical oncologists, radiation oncologists, patho- gists, and radiologists. This new dimension has been driven by the advent of new therapies and by closer interaction among all of these groups at academic meetings. This is to be applauded and has inevitably lead to improvements in the management of our patients.

Basic Science.- The Cell.- Animal Models in Genitourinary Malignancies.- Clinical Aspects and Investigations.- Radiological Investigations in Genitourinary Cancer.- Hematuria and Hematospermia: Clinical Evaluation and Principles of Management.- Nuclear Medicine in Urological Cancer.- Anesthesic Considerations in Genitourinary Cancer Patients.- Laparoscopy in Urological Oncology.- Clinical Trials and Their Principles.- Principles of Chemotherapy for Genitourinary Cancer.- Principles of Radiotherapy in Urologic Tumors.- Clinical Emergencies in Genitourinary Cancers.- Renal Failure, Dialysis, and Transplantation: Management of Tumors in Solitary Kidney and Bilateral Renal Tumors.- Diet and Genitourinary Cancer.- Systemic Genitourinary Oncology.- Renal Cell Carcinoma: Overview.- Nonsurgical Management of Metastatic Renal Cell Carcinoma.- Tumors of the Adrenal Gland.- Superficial Bladder Cancer.- Upper Urinary Tract Transitional Cell Carcinoma.- Surgical Management: Cystectomy and Urinary Diversion.- Multidisciplinary Care of Invasive Bladder Cancer: Emerging Roles of Chemotherapy.- Management of Metastatic Bladder Cancer.- Urethral Cancer (Excluding Penile Cancer).- Germ Cell Tumors.- Radiotherapy in the Management of Testicular Germ Cell Tumors.- Epidemiology, Pathology and Pathogenesis.- Clinical Presentation, Diagnosis, and Staging.- Surgical Management of Carcinoma of the Prostate.- Expectant Management of Early Prostate Cancer.- Radiation Therapy for Clinically Localized Prostate Cancer.- Endocrine Manipulation.- Hormone-Refractory Prostate Cancer: A Rational Approach to Chemotherapy.- Investigational Therapies for Prostate Cancer.- Cancer of the Penis and Scrotum.- Nonurological Cancers Affecting the Urinary Tract.

Urological oncology is a subject of enormous interest to large numbers of uro- gists throughout the world, particularly with our increasing understanding of the possible causes and pathogenesis of the condition. As Editor-in-Chief of one of the urological journals, I can attest to this interest; the largest percentage of the papers I receive for review each year relate to either clinical or experime- tal urological oncology. It used to be that the manuscripts concerned mainly surgical techniques, but now this has extended to new technologies, dia- nostic methods, randomized pharmaceutical clinical trials, and thoughtful and complex experimental studies into the genesis of urological cancer. This is all evidence of our increasing interest in the topic. In addition to this, we have come to understand the management of urolo- cal cancer is not in the hands of a single discipline. The advent of multidis- plinary team meetings has made us realize that there is a hugely signi? cant role to be played by urologists, medical oncologists, radiation oncologists, patho- gists, and radiologists. This new dimension has been driven by the advent of new therapies and by closer interaction among all of these groups at academic meetings. This is to be applauded and has inevitably lead to improvements in the management of our patients.